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n the Treatment of Patients With Long De Novo
esions in Small Native Coronary Arteries (C-SIRIUS)
rick Schampaert, MD,* Eric A. Cohen, MD,† Michael Schlu¨ter, PHD,‡ Franc¸ois Reeves, MD,§
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effrey J. Popma, MD, FACC,# for the C-SIRIUS Investigators
ontreal, Toronto, Calgary, and Halifax, Canada; Hamburg, Germany; and Boston, Massachusetts
OBJECTIVES We assessed the safety and effectiveness of the sirolimus-eluting stent (SES) in treating single
de novo long lesions in small native coronary arteries compared to an identical bare metal
stent (BMS).
BACKGROUND The SES was previously demonstrated to reduce restenosis significantly. However, patients
with long lesions in small vessels have not been well studied and may define a group at very
high risk.
METHODS The Canadian Study of the Sirolimus-Eluting Stent in the Treatment of Patients With Long
De Novo Lesions in Small Native Coronary Arteries (C-SIRIUS) was a multicenter,
randomized, double-blind trial comparing SES versus identical BMS. The primary end point
was in-stent minimal lumen diameter (MLD) at eight months. Secondary end points
included angiographic restenosis at 8 months, target lesion revascularization (TLR), and
major adverse cardiac events (MACE) at 270 days.
RESULTS A total of 100 patients were enrolled at eight Canadian sites. The in-stent MLD at eight
months was 2.46 0.37 mm in the SES compared with 1.49 0.75 mm in the BMS (a 65%
increase, p  0.001). Angiographic restenosis occurred in 1 of 44 SES patients (2.3%, with
no in-stent restenosis) and in 23 of 44 BMS patients (52.3%, p  0.001). At 270 days, there
were two clinically driven TLRs in the SES (4%) and nine in the BMS (18%, p 0.05). The
Kaplan-Meier estimate of freedom from MACE at 270 days was 96.0% for SES patients and
81.7% for BMS patients (p  0.029).
CONCLUSIONS Patients with long lesions in small vessels are at very high risk of restenosis. In these patients,
the SES dramatically reduces the risk of restenosis at eight months, translating into an
excellent clinical outcome at nine months. (J Am Coll Cardiol 2004;43:1110–5) © 2004 by
the American College of Cardiology Foundationi
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Ctent implantation has become the standard percutaneous
oronary intervention (PCI) (1–3). However, in-stent reste-
osis (ISR) within three to eights months has continued to
imit the long-term success of this therapy (4). Neointimal
See page 1116
yperplasia has been identified as the main mechanism of
SR (5,6). Predictors of ISR include a reference vessel
iameter smaller than 3.0 mm, lesion lengths above 10 mm,
nd diabetes mellitus (7–9). Although intracoronary brachy-
herapy is available to treat established ISR (10), stents
luting pharmaceutical agents capable of suppressing neo-
From the *Hoˆpital du Sacre´-Coeur de Montre´al, Montreal, Canada; †Sunnybrook
nd Women’s College Health Sciences Centre, Toronto, Canada; ‡Center for
ardiology and Vascular Intervention, Hamburg, Germany; §Centre Hospitalier de
’Universite´ de Montre´al, Pavillon Notre-Dame, Montreal, Canada; Calgary Heart
entre, Calgary, Canada; ¶Queen Elizabeth II Health Science Centre, Halifax, Nova
cotia, Canada; and #Brigham and Women’s Hospital, Boston, Massachusetts. This
tudy was sponsored by Cordis Canada, a Johnson & Johnson Company, the
anufacturer of the study stents.
Manuscript received November 6, 2003; revised manuscript received January 6,2004, accepted January 12, 2004.ntimal hyperplasia represent a promising approach to pre-
ent ISR (11).
Preclinical experiments of such an agent, sirolimus (rapa-
ycin), suggested efficacy and safety (12,13). A powerful
atural immunosuppressive macrocyclic lactone, it inhibits
ytokine-mediated proliferation and migration of lympho-
ytes and smooth muscle cells (14). Incorporated into a
iocompatible non-erodable stent polymer, sirolimus is
eleased into the stented vessel segment over a period of 90
ays.
Four clinical trials with the sirolimus-eluting stent (SES)
ave enrolled patients with de novo lesions in native
oronary arteries, with a pattern of increasing lesion com-
lexity (determined by vessel size and lesion length) in
uccessive trials. The “First-in-Man” study (15) restricted
reatment to the implantation of a single 18-mm stent in
essels 3.0 to 3.5 mm in diameter, guided by intravascular
ltrasound. The subsequent Randomized Study with the
irolimus-Coated Bx-VELOCITY Balloon-Expandable
tent in the Treatment of Patients with De Novo Native
oronary Artery Lesions (RAVEL) (16) included vessels
.5 to 3.5 mm in diameter, but still to be covered with a
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March 17, 2004:1110–5 Sirolimus-Eluting Stents in Small Arteriesingle stent. The pivotal Sirolimus-Eluting Stent in De
ovo Native Coronary Lesions (SIRIUS) trial (17) enrolled
atients with longer lesions of 15 to 30 mm, again in 2.5 to
.5 mm vessels. Finally, in E-SIRIUS (18), patients with a
arget lesion length of 15 to 32 mm in smaller vessels 2.5 to
.0 mm in diameter, were randomized to the SES versus a
are metal stent (BMS) of identical architecture.
During the same period, in Canada we conducted a
andomized, multicenter trial based on the same protocol as
-SIRIUS, targeting the same patients with long lesions,
otentially requiring multiple stents, in small coronary
rteries—all conditions that are known to increase the risk
f restenosis. Contemporary interventional techniques, in-
luding direct stenting, were allowed.
ATIENTS AND METHODS
atients. This study was a randomized, double-blind trial
nvolving eight Canadian teaching hospitals (Appendix).
atients were at least 18 years old, with documented angina
ectoris (Canadian Cardiovascular Society angina class 1 to
), unstable angina (Braunwald classification B and C, I or
I), or silent ischemia. Their PCI target had to be a single de
ovo lesion in a native vessel, between 15 and 32 mm in
ength, and with a diameter stenosis of 50% to 99%. The
essel diameter was limited to 2.5 to 3.0 mm. All angio-
raphic criteria were based on visual assessment. Major
xclusion criteria were the same as E-SIRIUS (18). The
tudy protocol was approved by the ethics committee at each
articipating center, and all patients gave written informed
onsent.
tudy stents. The control stents used were the bare metal
x-VELOCITY stent (J&J Cordis, Miami Lakes, Florida),
hich is a balloon-expandable, tubular 316L stainless-steel
tent pre-mounted on a monorail balloon-dilation catheter.
he study stents, using the same Bx-VELOCITY platform,
ad a 5-m coating consisting of a blend of 33% sirolimus
nd 67% of a non-erodable polymer. The drug-polymer
atrix contains 140 g of sirolimus per cm2 of surface area.
drug-free polymer topcoat serves as a control drug release
arrier, such that 80% of sirolimus is released within 30 days
f implantation and with no residual drug by 90 days. The
ES (brand name, Cypher) is visually and radiographically
ndistinguishable from its uncoated counterpart, allowing
Abbreviations and Acronyms
BMS  bare metal stent
ISR  in-stent restenosis
MACE  major adverse cardiac events
MLD  minimal lumen diameter
PCI  percutaneous coronary intervention
QCA  quantitative coronary angiography
SES  sirolimus-eluting stent
TLR  target lesion revascularizationor the double-blind design of the trial. otudy procedures. As previously described (18), patients
ere randomly assigned either to sirolimus or control stents
y means of sealed randomization envelopes. Neither the
perator nor the patient knew which stent would be
mplanted.
According to standard care, patients were pre-medicated
ith 81 to 325 mg of aspirin, begun at least 12 h before the
rocedure, and clopidogrel, administered as a loading dose
f 300 mg before or immediately after the procedure.
uring the procedure, intravenous boluses of heparin were
dministered to maintain an activated clotting time in excess
f 250 s. The use of glycoprotein IIb/IIIa receptor antago-
ists was left to the investigator’s discretion.
Stent implantation followed current accepted techniques,
s described (18). One distinguishing feature of this study,
ompared with previous trials, was to allow “direct stenting”
without lesion pre-dilation) in centers where this was
tandard practice. The decision to pre-dilate or not was left
o the investigator. Heparin was discontinued immediately
fter the procedure. Patients were discharged on a regimen
f aspirin (81 to 325 mg/day indefinitely) and clopidogrel
75 mg/day) for two months only.
ollow-up. Patients were evaluated clinically at 30, 90,
80, and 270 days. A repeat angiographic study was sched-
led after eight months in all patients.
efinitions. At the outset we distinguished between “in-
tent” and “in-lesion” angiographic variables, with the
ormer referring to the vessel segment inside the stent and
he latter including the 5-mm vessel segments adjacent to
he proximal and distal stent edges. Late luminal loss was
efined as the difference between the minimal lumen
iameter (MLD) at eight months and the MLD
ost-procedure.
tudy end points. The primary end point of this study
as in-stent MLD at eight months, determined by quan-
itative coronary angiography (QCA). Secondary end
oints included: eight-month angiographic in-lesion MLD;
n-stent and in-lesion angiographic restenosis (a 50%
iameter stenosis by QCA); major adverse cardiac events
MACE)—a composite end point comprising death, myo-
ardial infarction, emergent coronary artery bypass surgery,
nd clinically driven repeat target lesion revascularization
TLR)—all at nine months; and TLR at nine months. A
linically driven TLR procedure was defined as one done in
esponse to recurrent angina and/or documented ischemia
n noninvasive tests (all recorded prior to repeat angiogra-
hy), with 50% diameter stenosis by QCA, or 70%
iameter stenosis by QCA in the absence of symptoms.
Offline QCA at baseline, post-procedure, and after eight
onths was performed by an independent core laboratory
Brigham and Women’s Hospital Angiographic Core Lab-
ratory, Boston, Massachusetts). All clinical end points were
djudicated by an independent clinical events committee.
ata management and statistical methods. At each par-
icipating center, patients’ data were prospectively recorded
n standard case report forms. Complete data monitoring
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Sirolimus-Eluting Stents in Small Arteries March 17, 2004:1110–5as performed by an independent clinical research consult-
ng firm (DT Consultant, Montreal, Canada), which for-
arded the completed case report forms to the study
oordinating center for data entry and analysis. Treatment
llocation was unblinded at Harvard Clinical Research
nstitute after nine-month clinical follow-up for analysis.
able 1. Baseline Characteristics*
Sirolimus Stent
(n  50)
Control Stent
(n  50)
Age (yrs) 60.3  10.6 60.7  9.1
Male gender (%) 70 68
isk factors
Diabetes mellitus (%) 24 24
Hyperlipidemia (%) 84 86
Hypertension (%) 56 48
Current smoking (%) 36 38
istory
Prior myocardial infarction (%) 48 42
Prior PCI (%) 8 8
Prior CABG (%) 6 2
ngina†
Stable (%) 10 14
Unstable (%) 48 54
Post-myocardial infarction (%) 22 8
ultivessel disease (%) 46 34
argeted artery (%)
LAD 32 40
LCX 22 24
RCA 46 36
CC/AHA lesion class B2–C (%) 64 54
eference vessel diameter (mm) 2.65  0.30 2.62  0.35
esion length (mm) 14.5  6.3 12.6  5.2
Mean  SD; †According to the Braunwald classification.
ACC/AHA  American College of Cardiology/American Heart Association;
ABG  coronary artery bypass grafting; CCS  Canadian Cardiovascular Society;
AD  left anterior descending coronary artery; LCX  left circumflex coronary
rtery; PCI  percutaneous coronary intervention; RCA  right coronary artery.
Table 2. Quantitative Coronary Angiography
Sirolimus Sten
Before procedure
Reference vessel diameter (mm) 2.65  0.30
MLD (mm) 0.77  0.29
Diameter stenosis (%) 70.9  10.6
After procedure
MLD in-stent (mm) 2.53  0.30
MLD in-lesion (mm)* 2.23  0.35
Diameter stenosis in-stent (%) 6.1  9.1
Diameter stenosis in-lesion (%) 17.5  7.1
At 8-month follow-up
MLD in-stent (mm) 2.46  0.37
MLD in-lesion (mm) 2.15  0.35
Late luminal loss in-stent (mm) 0.12  0.37
Late luminal loss in-lesion (mm) 0.12  0.35
Diameter stenosis in-stent (%) 9.3  10.6
Diameter stenosis in-lesion (%) 20.5  10.3
Angiographic restenosis†
In-stent 0/44 (0.0%)
In-lesion 1/44 (2.3%)
Continuous variables are presented as mean (SD). *Includes th
stenosis 50% at follow-up.
Acute luminal gain  difference between MLD after pro
luminal loss  difference between MLD at 8 months and MLD aowever, individual patient assignment has remained
linded for unbiased clinical follow-up to five years. All data
ere held at the study coordinating center, but the authors
f this report had full access to them.
Based on the hypothesis that in-stent MLD by QCA at
ight months would be 1.6 mm for the control stent and 2.4
m for the SES, with a common standard deviation of 0.7
m, detecting this difference with an 80% power and a
wo-sided alpha error of 5%, would require a sample size of
60 patients (30 patients per study arm). Adjusting for an
0% compliance with eight-month angiographic follow-up,
he sample size of 100 patients was judged adequate. All
nalyses were based on the intention-to-treat principle.
ontinuous variables are presented as mean value  SD,
ith differences between groups assessed by the Student
npaired t test. Discrete variables are presented as counts
nd percentages, with differences between groups assessed
y the Fisher exact test. The Kaplan-Meier method was
sed to analyze the occurrence of the composite end point of
ACE during the nine-month period of follow-up, with
ifferences between event-free survival curves assessed by
og-rank test. Statistical significance was assumed at the 5%
evel (p  0.05).
ESULTS
etween November 2001 and April 2002, we enrolled 102
atients. Two patients were randomized (one in each group)
ut subsequently deregistered because no study stent im-
lantation was attempted (one patient underwent coronary
rtery bypass grafting after failure to cross the lesion with a
uidewire and one patient was withdrawn from the study
fter failed predilation with standard balloons). Thus, 100
atients entered the trial for end point analysis, with 50
ntrol Stent Difference [95% CI] p
.62  0.35 0.03 [0.10, 0.16] 0.61
.82  0.26 0.05 [0.16, 0.06] 0.38
8.5  10.0 2.4 [1.6, 6.5] 0.24
.50  0.28 0.03 [0.09, 0.14] 0.67
.17  0.37 0.07 [0.07, 0.21] 0.35
5.2  10.6 0.9 [3.0, 4.9] 0.64
8.5  10.0 1.0 [4.4, 1.0] 0.57
.49  0.74 0.97 [0.72, 1.22] 0.001
.39  0.69 0.77 [0.54, 1.00] 0.001
.02  0.69 0.91 [1.14, 0.67] 0.001
.79  0.74 0.67 [0.91, 0.42] 0.001
4.2  26.5 34.8 [43.4, 26.2] 0.001
7.8  24.5 27.3 [35.3, 19.4] 0.001
/44 (45.5%) 45.5% [60.2%, 30.7%] 0.001
/44 (52.3%) 50.0% [65.4%, 34.6%] 0.001
m segments proximal and distal to the stent edges; †diameter
and MLD before procedure; CI  confidence interval; latet Co
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March 17, 2004:1110–5 Sirolimus-Eluting Stents in Small Arteriesatients receiving an SES and 50 patients receiving un-
oated control BMS. Baseline characteristics of the patients
Table 1) were well matched between groups, with 24% of
atients having diabetes mellitus.
Device success, defined as the achievement of 50%
esidual diameter stenosis with the assigned stent, was 100%
n both groups.
The mean lesion length as measured by QCA was 13.6
.8 mm, in vessels with a mean reference diameter of 2.63
0.33 mm. Glycoprotein IIb/IIIa inhibitors were admin-
stered to 53% of patients. The average number of stents
mplanted was 1.5  0.7 per patient, with two or more
tents implanted in 40% of patients. This resulted in a mean
otal stent length of 23.8  8.4 mm and a stent length to
esion length ratio of 1.8  0.8. Direct stenting was
erformed in 31% of cases. Of the stented lesions, 64% were
ost-dilated (using a shorter balloon in one-half the cases),
ith a mean maximum pressure of 17.3  3.4 atm and a
ominal balloon to artery ratio of 1.0  0.1.
Immediate post-procedure results were similar for SES
nd BMS, with a mean in-stent MLD of 2.51  0.29 mm,
nd residual in-stent and in-lesion stenoses of 5.7% and
7.9%, respectively.
igure 1. Late luminal loss by quantitative coronary angiography. Proximal
dge: the 5-mm proximal to the stent. Distal edge: the 5-mm distal to the
tent. Late loss was defined as the difference between the in-stent minimal
umen diameter at follow-up and the post-procedure in-stent minimal
umen diameter.
Table 3. Major Adverse Cardiac Events Out t
Sirolimus Stent
(n  50)
Event*
Death 0 (0%)
Myocardial infarction 1 (2.0%)
Q-wave 0 (0%)
Non–Q-wave† 1 (2.0%)
CABG 1 (2.0%)
Clinically driven TLR 2 (4.0%)
Total 2 (4.0%)
*Non-hierarchical listing; †non–Q-wave myocardial infarction
to more than twice the upper limit of normal, with elevated
pathological Q waves.
CABG  coronary artery bypass grafting; CI  confiden
coronary intervention.Eight-month angiographic follow-up was available in
8% of patients, with 44 patients in each group. The
ight-month in-stent MLD, the primary end point, was
ignificantly greater in the SES group at 2.46 0.37 mm vs.
he BMS group at 1.49  0.75 mm (a 65% increase, p 
.001) (Table 2). The corresponding late luminal loss was
educed by 90%, from 1.02  0.69 mm to 0.12  0.37 mm
p  0.001) (Table 2). The eight-month in-lesion MLD
as also significantly improved in the SES group compared
o the BMS group (Table 2). Consequently, the in-lesion
ate luminal loss was significantly reduced in the SES
atients (Table 2), with an effect demonstrated both at the
roximal and distal stent edges (Fig, 1). Angiographic
estenosis occurred in 1 of 44 SES patients (2.3%), with no
SR, and in 23 of 44 BMS patients (52.3%, p 0.001). The
ingle SES patient with in-lesion restenosis had a 58%
tenosis proximal to the SES stent. The relative reductions
n eight-month binary restenosis associated with use of the
ES were thus 96% within the lesion and 100% within the
tent. No aneurysms were seen.
Major adverse cardiac events at 270 days for all 100
atients are listed in Table 3. There were no deaths and no
-wave myocardial infarctions. Stent thrombosis occurred
n one patient in each group (on day 8 in an SES patient
fter an initially successful intervention involving three
tents in a small right coronary artery, and on day 57 in a
MS patient), requiring TLR in both cases. Eight addi-
ional clinically driven TLR procedures occurred in the
MS group and one such procedure in the SES group, for
total TLR rate at nine months of 18% and only 4%,
espectively (p  0.05). Only two BMS patients sustained a
on-clinically driven TLR following repeat angiography at
ight months. Consequently, the Kaplan-Meier estimate of
reedom from MACE at 270 days was 96.0% for SES
atients and 81.7% for BMS patients (p  0.029) (Fig. 2).
ISCUSSION
ompared with previous trials (15–17), the patients en-
olled in this Canadian multicenter controlled trial, along
ith the E-SIRIUS patients (18), had a higher clinical-risk
Days of Follow-Up
rol Stent
 50)
Difference
[95% CI] p
%) 0% [–, –] 1.00
.0%) 2.0% [8.7, 4.7] 0.58
%) 0% [–, –] 1.00
.0%) 2.0% [8.7, 4.7] 0.58
%) 2.0% [1.9%, 5.9%] 0.25
8.0%) 14.0% [26.0%, 2.0%] 0.05
8.0%) 14.0% [26.0%, 2.0%] 0.05
ed as elevation of post-procedure creatine kinase serum levels
e kinase-MB isoenzyme serum levels, in the absence of new
rval; TLR  target lesion revascularization by percutaneouso 270
Cont
(n
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Sirolimus-Eluting Stents in Small Arteries March 17, 2004:1110–5rofile for restenosis: long target lesions, small target vessels,
ultiple stents in 40% of cases, and a mean implanted stent
ength of 23.8 mm. This is reflected in the progressive
ncrease of the in-lesion restenosis rate of the BMS group:
6.6% in RAVEL (16), 36.3% in SIRIUS (17), 42.3% in
-SIRIUS, and 52.3% in our trial. Despite the higher risk
rofile of our patients, the eight-month in-stent and in-
esion MLDs were well maintained in the SES patients.
ate luminal loss at the proximal and distal edges of the
ES was reduced by 77% and 100%, respectively, compared
ith the BMS, suggesting a true protective effect of the SES
t the stent margins. Consequently, the angiographic reste-
osis rate following SES implantation was only 2.3%, with
o ISR. These findings confirm the efficacy of the SES to
revent restenosis, as observed in all previous trials (15–18).
hus, the need for a clinically driven revascularization
rocedure, prompted by recurrent angina and/or docu-
ented ischemia, fell from 18% in BMS patients to 4% in
ES patients. This means that for every 1,000 patients
ndergoing stent implantation for a native coronary artery
esion of the type included in this study, 140 patients may be
pared from clinical restenosis and repeat intervention at
ine months by initial treatment with SES.
Because the same SES was used in four randomized trials,
ertain observations regarding the SES patients across the
rials may be relevant. The somewhat higher in-lesion
estenosis rate observed in SIRIUS (8.9%), compared with
AVEL (0%), E-SIRIUS (5.9%), and C-SIRIUS (2.3%),
as associated with more proximal margin restenosis:
.8% in SIRIUS (especially in patients with the smallest
essels), compared with 0%, 2.1%, and 2.3% in RAVEL,
-SIRIUS, and C-SIRIUS, respectively. This difference
ould be related to subtle but more frequent or pro-
ounced proximal edge trauma during pre-dilation, stent
mplantation, or post-deployment dilation, overwhelm-
ng the protective effect at the SES proximal margin. The
se of direct stenting in E-SIRIUS and C-SIRIUS may
lso have limited proximal edge trauma and subsequent
estenosis in some patients. Taken together with the
bservation that the total stent length to lesion length
atio of 1.8 in our trial was identical to that in RAVEL
nd E-SIRIUS suggests that meticulous (and generous)
Figure 2. Survival free from major adverse cardiac eveoverage of all the injured and diseased vessel area
ppears to be desirable.
ONCLUSIONS
he C-SIRIUS demonstrated that patients with long le-
ions in small vessels are at very high risk of restenosis. In
hese patients, the SES dramatically reduced the risk of
estenosis, with no ISR at eight months, translating into an
xcellent clinical outcome at nine months. Ongoing
ollow-up will evaluate the durability of these clinical
enefits over the next four years.
eprint requests and correspondence: Dr. Erick Schampaert,
oˆpital du Sacre´-Coeur de Montre´al, 5400 Bl. Gouin O., Mon-
re´al, Que´bec, Canada H4J 1C5. E-mail: erick.schampaert.hsc@
sss.gouv.qc.ca.
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